Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Nephrology · Fanconi Renotubular Syndrome 4

Standard Care: Managing Kidneys and Blood Sugar

At a Glance

FRTS4 care replaces substances the kidneys lose, protects bone health, and monitors for calcium buildup and chronic kidney disease. If HNF4A-MODY develops, sulfonylureas may control blood sugar, but kidney function guides dosing and some people later need insulin.

Managing Fanconi Renotubular Syndrome 4 (FRTS4) requires a “two-front” approach that addresses both the kidneys and the pancreas. Because the condition is so rare, there is no single “standard dose” for everyone. Instead, doctors use a strategy of frequent monitoring and dose adjustment to meet your body’s specific needs [1]. Never adjust fluid intake or supplement doses on your own without consulting your care team, as doing so can be unsafe depending on your kidney function and potassium levels.

Managing Kidney and Bone Health

The primary goal of kidney treatment is to replace what the proximal tubules are losing and to protect the bones from softening (rickets).

  • Correcting Acidosis: To prevent the blood from becoming too acidic (metabolic acidosis), patients take “alkali” supplements like sodium bicarbonate or potassium citrate. These act as a chemical buffer. Because the “leakiness” in FRTS4 can be high, your nephrology team will titrate (adjust) the dose based on blood bicarbonate, potassium, eGFR, blood pressure, and volume status [2][1]. Note that sodium bicarbonate adds sodium load, and potassium citrate can be hazardous if potassium levels are high or kidney function is reduced.
  • Treating Phosphate Wasting: Because the kidneys leak phosphate, levels in the blood can drop, leading to rickets [3]. Treatment typically involves:
    • Phosphate Supplements: Liquid or tablet forms taken several times a day to maintain bone strength [4].
    • Active Vitamin D (Calcitriol): This form of vitamin D affects vitamin D/PTH physiology and, alongside phosphate, aids bone health [5].
  • Preventing Complications: While these supplements are necessary, they can sometimes cause calcium to build up in the kidneys (nephrocalcinosis). Your care team will use regular urine tests and kidney ultrasounds to find the “sweet spot” where bones are healthy but the kidneys are protected [3][5].

Managing Diabetes (HNF4A-MODY)

When the condition transitions into the diabetic phase, the treatment is often different from common Type 1 or Type 2 diabetes.

  • Sulfonylureas (First-Line): Many patients with HNF4A-MODY respond very well to oral medications called sulfonylureas [6][7]. These pills help the pancreas release its stored insulin. They are often highly effective and can sometimes replace insulin injections entirely for many years [8][9].
  • CKD and Hypoglycemia Risks: Sulfonylurea choice and dosing must be individualized to your eGFR (kidney function). Medications like glyburide (glibenclamide) are generally avoided when kidney function is reduced because they carry a high risk of prolonged, severe low blood sugar (hypoglycemia). Your doctor must carefully choose the specific drug to minimize this risk [10][11].
  • Transition to Insulin: Over time, the pancreas may gradually lose its ability to make enough insulin. A portion of patients may eventually need to add insulin injections to their regimen to maintain healthy blood sugar levels [12][13].

Building Your Care Team

Because FRTS4 affects multiple systems, your “medical home” should coordinate between several specialists:

  • Nephrologist: Manages the Fanconi syndrome, electrolyte supplements, and monitors for chronic kidney disease (CKD) [14].
  • Endocrinologist: Manages the transition from neonatal low blood sugar to HNF4A-MODY [15].
  • Medical Geneticist: Assists with variant interpretation and testing for other family members [16].

Some case reports have noted hearing loss or eye/liver abnormalities with certain HNF4A variants [17][18]. While routine syndrome-specific screening for these isn’t universally established, your doctors will investigate these areas if symptoms arise or as part of standard diabetes/CKD care. Because FRTS4 is a progressive condition—with a risk of reaching CKD Stage 3 by adulthood—consistent, long-term follow-up with these specialists is the most effective way to protect your overall health [3].

Common questions in this guide

What medicines are used to treat the kidney problems in FRTS4?
Doctors may use sodium bicarbonate or potassium citrate to correct acidosis, along with phosphate and active vitamin D (calcitriol) to support bone health. Doses are adjusted using blood bicarbonate, potassium, kidney function, blood pressure, and fluid status. Do not change fluids or supplements without guidance from your care team.
How can FRTS4 treatment protect bones without harming the kidneys?
Phosphate and calcitriol can treat phosphate-wasting rickets, but supplements may contribute to calcium buildup in the kidneys. Regular urine tests and kidney ultrasounds help clinicians balance bone health with the risk of nephrocalcinosis.
Is a sulfonylurea safe if I have HNF4A-MODY and reduced kidney function?
Sulfonylureas often work well for HNF4A-MODY, but the specific medicine and dose must be matched to kidney function. Glyburide, also called glibenclamide, is generally avoided when kidney function is reduced because it can cause severe and prolonged low blood sugar. Your clinician should choose and monitor the treatment.
Will HNF4A-MODY eventually require insulin?
Not everyone with HNF4A-MODY needs insulin right away, because sulfonylureas may control blood sugar for many years. Some people gradually make less insulin and eventually need insulin injections to maintain healthy blood sugar levels.
How often should kidney ultrasounds be done during FRTS4 treatment?
The timing of kidney ultrasounds is individualized based on treatment, kidney function, and previous findings. Your nephrology team can set the schedule and use urine tests with ultrasound to monitor for nephrocalcinosis or kidney stones.
Which specialists should be involved in FRTS4 care?
A nephrologist manages the kidney disorder, electrolyte replacement, and chronic kidney disease monitoring. An endocrinologist manages HNF4A-MODY and blood sugar, while a medical geneticist helps interpret variants and assess family members.

Get notified when new evidence is published on Fanconi renotubular syndrome 4 with maturity-onset diabetes of the young.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    Renal Tubular Acidosis.

    Bagga A, Sinha A

    Indian journal of pediatrics 2020; (87(9)):733-744 doi:10.1007/s12098-020-03318-8.

    PMID: 32591997
  2. 2

    Descriptive cohort study of transient isolated tubular acidosis in early childhood: experience from a rare kidney disease expert center.

    Charfi H, Bertholet-Thomas A, Bacchetta J, et al.

    European journal of pediatrics 2025; (184(10)):613 doi:10.1007/s00431-025-06394-0.

    PMID: 40935900
  3. 3

    Phenotypic Spectrum of HNF4α-Associated Fanconi Renotubular Syndrome.

    Emma F, Böckenhauer D, Mallett AJ, et al.

    Kidney international reports 2026; (11(8)):106616 doi:10.1016/j.ekir.2026.106616.

    PMID: 42440446
  4. 4

    Case report: Reversible Fanconi syndrome due to vitamin D deficiency in a patient with epilepsy harbouring a pathogenic variant in the SLC34A1 gene.

    Improda N, Rosanio FM, Annicchiarico Petruzzelli L, et al.

    Frontiers in endocrinology 2025; (16()):1553032 doi:10.3389/fendo.2025.1553032.

    PMID: 40225330
  5. 5

    Rickets guidance: part II-management.

    Haffner D, Leifheit-Nestler M, Grund A, Schnabel D

    Pediatric nephrology (Berlin, Germany) 2022; (37(10)):2289-2302 doi:10.1007/s00467-022-05505-5.

    PMID: 35352187
  6. 6

    Treatment Options for Patients with Maturity-Onset Diabetes of the Young (MODY): A Systematic Review of Literature: 2026 Update.

    Zagaroli L, Di Berardino A, Petragnano F, et al.

    Diabetes therapy : research, treatment and education of diabetes and related disorders 2026; (17(7)):959-983 doi:10.1007/s13300-026-01884-2.

    PMID: 42295651
  7. 7

    Case Report: Beyond type 1 diabetes: a case of delayed MODY1 diagnosis and successful transition to sulfonylurea therapy.

    Gulisano C, Aloi C, Salina A, et al.

    Frontiers in medicine 2025; (12()):1590935 doi:10.3389/fmed.2025.1590935.

    PMID: 40486195
  8. 8

    MODY in Ukraine: genes, clinical phenotypes and treatment.

    Globa E, Zelinska N, Elblova L, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2017; (30(10)):1095-1103.

    PMID: 28862987
  9. 9

    Clinical characteristics, treatment, and treatment switch after molecular-genetic classification in individuals with maturity-onset diabetes of the young: Insights from the multicenter real-world DPV registry.

    Lanzinger S, Laubner K, Warncke K, et al.

    Journal of diabetes 2024; (16(11)):e70028 doi:10.1111/1753-0407.70028.

    PMID: 39511990
  10. 10

    Clinical Management of Women with Monogenic Diabetes During Pregnancy.

    Dickens LT, Naylor RN

    Current diabetes reports 2018; (18(3)):12 doi:10.1007/s11892-018-0982-8.

    PMID: 29450745
  11. 11

    A Case of Oral Semaglutide for Treatment of Hepatocyte Nuclear Factor 4A Maturity-Onset Diabetes of the Young.

    Grennan KN, Singh D, Chindris AM, Wilson JR

    AACE endocrinology and diabetes 2026; (13(2)):177-179 doi:10.1016/j.aed.2025.12.002.

    PMID: 41938282
  12. 12

    Novel Treatment Options in Patients with Maturity-Onset Diabetes of the Young.

    Müssig K

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2025; (133(1)):51-58 doi:10.1055/a-2436-7723.

    PMID: 39379059
  13. 13

    Identification and precision therapy for three maturity-onset diabetes of the young (MODY) families caused by mutations in the HNF4A gene.

    Zhang J, Jiang Y, Li J, et al.

    Frontiers in endocrinology 2023; (14()):1237553 doi:10.3389/fendo.2023.1237553.

    PMID: 37711893
  14. 14

    Hepatocyte Nuclear Factor-4 Alfa Mutation Associated with Hyperinsulinaemic Hypoglycaemia and Atypical Renal Fanconi Syndrome: Expanding the Clinical Phenotype.

    Improda N, Shah P, Güemes M, et al.

    Hormone research in paediatrics 2016; (86(5)):337-341 doi:10.1159/000446396.

    PMID: 27245055
  15. 15

    Neonatal Hyperinsulinemia and Maternal Diabetes Associated With a Hepatocyte Nuclear Factor 4 Alpha (HNF4A) Variant.

    Takasugi Y, Nakagawa R, Ono H, et al.

    Cureus 2026; (18(4)):e107058 doi:10.7759/cureus.107058.

    PMID: 42147507
  16. 16

    Novel Fanconi renotubular syndromes provide insights in proximal tubule pathophysiology.

    Lemaire M

    American journal of physiology. Renal physiology 2021; (320(2)):F145-F160 doi:10.1152/ajprenal.00214.2020.

    PMID: 33283647
  17. 17

    HNF4A-related Fanconi syndrome in a Chinese patient: a case report and review of the literature.

    Liu J, Shen Q, Li G, Xu H

    Journal of medical case reports 2018; (12(1)):203 doi:10.1186/s13256-018-1740-x.

    PMID: 30005691
  18. 18

    Heterozygous recurrent HNF4A variant p.Arg85Trp causes Fanconi renotubular syndrome 4 with maturity onset diabetes of the young, an autosomal dominant phenocopy of Fanconi Bickel syndrome with colobomas.

    Sheppard SE, Barrett B, Muraresku C, et al.

    American journal of medical genetics. Part A 2021; (185(2)):566-570 doi:10.1002/ajmg.a.61978.

    PMID: 33251707

This page is for informational purposes only and does not constitute medical advice. Your nephrologist, endocrinologist, and geneticist should individualize supplements, fluids, and diabetes treatment based on kidney function and blood sugar.